Last edition
News about "Chairman and MD Glenn Saldanha "
Glenmark Eyes 10-15 percent India Growth by Prioritising High-Margin Branded Products
Glenmark Pharmaceuticals is targeting a compounded annual growth rate (CAGR) of 10–15 % for its India business over the next two to three years by shifting its focus up the value chain and expanding its portfolio of high-margin branded products.
Chairman And MD Glenn Saldanha | 19/08/2025 | By Darshana | 118
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members